Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile

Wu, Silin; Gu, Yajia; Huang, Yuying; Wong, Tyh-Chai; Ding, Hailin; Liu, Tengfei; Zhang, Yu; Zhang, Xiaobiao

doi:10.1007/s10528-017-9794-9

Cited by 43 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of them, miR-493-5p and miR-124-3p were significantly downregulated while miR-181b-5p was upregulated. Wu et al [41] also reported four upregulated (miRNAs hsa-miR-181b-5p, hsa-miR-181d, hsa-miR-191-3p, and hsa-miR-598) and two downregulated miRNAs (hsa-miR-3676-5p and hsa-miR-383) in NFPA samples. By performing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, they demonstrate that these differentially-expressed miRNAs are related to a series of biological processes and several signaling pathways [41].…”

Section: Discussionmentioning

confidence: 94%

“…Wu et al [41] also reported four upregulated (miRNAs hsa-miR-181b-5p, hsa-miR-181d, hsa-miR-191-3p, and hsa-miR-598) and two downregulated miRNAs (hsa-miR-3676-5p and hsa-miR-383) in NFPA samples. By performing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, they demonstrate that these differentially-expressed miRNAs are related to a series of biological processes and several signaling pathways [41]. Thus, these miRNAs may play a role in modulating the processes in NFPA progression, particularly miR-181b-5p, which needs further functional and mechanistic validations.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas

Chen

et al. 2019

Endocr J

View full text Add to dashboard Cite

Pituitary adenomas (PAs) are considered the most common intracranial tumor to cause serious morbidity because of dysregulated pituitary hormone secretions. Aberrant expression of microRNAs (miRNAs) is correlated with the development and function of the pituitary gland as well as the tumorigenesis of hypothalamic-pituitary axis-related pituitary tumors. In this study, we showed the differential expression patterns of miRNAs in NFPAs (nonfunctioning pituitary adenomas), GHPAs (growth hormone-secreting pituitary adenomas) and PRLPAs (prolactin-secreting pituitary adenomas) compared to those in three normal pituitary glands using the HiSeq 2000 sequencing system (Illumina). We validated miRNA expression using real-time quantitative polymerase chain reaction (RT-qPCR) analyses of samples from 73 patients (13 GHPAs, 42 NFPAs, and 18 PRLPAs) and 6 normal pituitary gland. We observed that miR-34c-3p was significantly downregulated in our PRLPA samples (p < 0.01), along with miR-34b-5p, miR-378 and miR-338-5p (all p < 0.05). In NFPAs, miR-493-5p was downregulated, and miR-181b-5p was significantly upregulated (p < 0.01). In GHPAs, miR-184 was significantly upregulated (p < 0.05). We observed that the tumor suppressive miR-124-3p was downregulated in both NFPAs and GHPAs. Taken together, we showed distinctive miRNA expression patterns in these three PAs, and these miRNA signatures in PA may have therapeutic potential as novel biomarkers for each type of PA.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 94%

Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas

Chen

et al. 2019

Endocr J

View full text Add to dashboard Cite

show abstract

“…Among these predicted potential target miRNAs, hsa-miR-24-2-59 is reported to be upregulated during hematopoietic cell terminal differentiation, suppressing MYC expression [29]. Hsa-miR-181b-5p may play a prominent role in pituitary adenoma as an effective biomarker and therapeutic target [30]. However, there are some limitations to this study, such as a small sample size and the in vitro research being conducted only on HL-60 cells.…”

Section: Discussionmentioning

confidence: 95%

Expression Profile Screening and Bioinformatics Analysis of Circrna, Lncrna and Mrna in Acute Myeloid Leukemia Drug-Resistance Cells

Meng

2019

Tjh

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy, and drug resistance and relapse are key factors in the failure of leukemia treatment. Studies have increasingly shown that circRNA and LncRNA play important roles in the development of tumors, but their roles remain unclear in the mechanism of AML resistance. Materials and Methods: Resistant AML cell line HL-60/ADM (adriamycin, ADM) was constructed and circRNA, LncRNA, and mRNA expression profiles were screened followed by high-throughput sequencing. Bioinformatics analysis was then carried out, and the circRNA-miRNA ceRNA network was constructed and confirmed using qRT-PCR analysis. Results: A total of 1824 circRNAs, 2414 LncRNAs, and 5346 mRNAs were screened for differentially expressed genes. Enrichment analysis was performed utilizing Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes, which mainly involved protein domain specific binding, transforming growth factor-β (TGF-β) receptor, and cellular metabolism. The mTOR signaling pathway, MAPK signaling pathway, RAP1 signaling pathway, and Akt signaling pathway were closely related to drug resistance. Conclusion: Our study provides a systematic outlook on the potential function of ncRNA in the molecular mechanisms of resistant AML cells. Hsa-circ-0000978 and hsa-circ-0000483 might serve as potential prognostic biomarkers and therapeutic targets of AML resistance.

show abstract

“…miRNAs are small non-coding RNAs that post-transcriptionally modulate gene expression, and whose expression is altered in several human neoplasia. For example, relevant for the topic of this review, a different miRNA expression pattern was observed in NFPAs and normal pituitary (136) with a significant influence on stem cell-related pathways, such as NOTCH (137). The field of miRNA is rapidly evolving and its application to different PASC populations might provide important novel information concerning the pathogenic mechanisms activated in these cells to originate PAs.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 97%

Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells

et al. 2020

View full text Add to dashboard Cite

Pituitary adenomas, accounting for 15% of diagnosed intracranial neoplasms, are usually benign and pharmacologically and surgically treatable; however, the critical location, mass effects and hormone hypersecretion sustain their significant morbidity. Approximately 35% of pituitary tumors show a less benign course since they are highly proliferative and invasive, poorly resectable, and likely recurring. The latest WHO classification of pituitary tumors includes pituitary transcription factor assessment to determine adenohypophysis cell lineages and accurate designation of adenomas, nevertheless little is known about molecular and cellular pathways which contribute to pituitary tumorigenesis. In malignant tumors the identification of cancer stem cells radically changed the concepts of both tumorigenesis and pharmacological approaches. Cancer stem cells are defined as a subset of undifferentiated transformed cells from which the bulk of cancer cells populating a tumor mass is generated. These cells are able to self-renew, promoting tumor progression and recurrence of malignant tumors, also conferring cytotoxic drug resistance. On the other hand, the existence of stem cells within benign tumors is still debated. The presence of adult stem cells in human and murine pituitaries where they sustain the high plasticity of hormone-producing cells, allowed the hypothesis that putative tumor stem cells might exist in pituitary adenomas, reinforcing the concept that the cancer stem cell model could also be applied to pituitary tumorigenesis. In the last few years, the isolation and phenotypic characterization of putative pituitary adenoma stem-like cells was performed using a wide and heterogeneous variety of experimental models and techniques, although the role of these cells in adenoma initiation and progression is still not completely definite. The assessment of possible pituitary adenoma-initiating cell population would be of extreme relevance to better understand pituitary tumor biology and to identify novel potential diagnostic markers and pharmacological targets. In this review, we summarize the most updated studies focused on the definition of pituitary adenoma stem cell phenotype and functional features, highlighting the biological processes and intracellular pathways potentially involved in driving tumor growth, relapse, and therapy resistance.

show abstract

Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile

Cited by 43 publications

References 38 publications

Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas

Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas

Expression Profile Screening and Bioinformatics Analysis of Circrna, Lncrna and Mrna in Acute Myeloid Leukemia Drug-Resistance Cells

Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells

Contact Info

Product

Resources

About